Search details
1.
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
Gynecol Oncol
; 180: 79-85, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38056115
2.
Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Gynecol Oncol
; 180: 170-177, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38211405
3.
Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer.
Int J Gynecol Cancer
; 2024 Jun 08.
Article
in English
| MEDLINE | ID: mdl-38851239
4.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36878237
5.
The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey.
Future Oncol
; 19(19): 1331-1342, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37476966
6.
Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics.
Future Oncol
; 19(16): 1113-1124, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37170823
7.
Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Future Oncol
; 18(4): 491-503, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34875854
8.
Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer.
Arch Gynecol Obstet
; 305(6): 1647-1654, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34993579
9.
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Gynecol Oncol
; 159(2): 491-497, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32951894
10.
Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer.
Cancer Treat Res Commun
; 39: 100800, 2024.
Article
in English
| MEDLINE | ID: mdl-38430610
11.
Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer.
Front Oncol
; 14: 1290719, 2024.
Article
in English
| MEDLINE | ID: mdl-38601762
12.
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Target Oncol
; 18(4): 531-541, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37233868
13.
Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.
Cancer Treat Res Commun
; 36: 100726, 2023.
Article
in English
| MEDLINE | ID: mdl-37301127
14.
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Pharmacoecon Open
; 6(6): 811-822, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36036344
15.
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
J Mark Access Health Policy
; 10(1): 2078474, 2022.
Article
in English
| MEDLINE | ID: mdl-35693379
16.
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Pharmacoeconomics
; 38(11): 1201-1218, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32794041
17.
Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
Leuk Lymphoma
; 60(4): 947-954, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30234407
18.
Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis.
Crit Rev Oncol Hematol
; 67(1): 64-70, 2008 Jul.
Article
in English
| MEDLINE | ID: mdl-18358737
19.
Venous and arterial thromboembolism in severe sepsis.
Thromb Haemost
; 99(5): 892-8, 2008 May.
Article
in English
| MEDLINE | ID: mdl-18449418
20.
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Lung Cancer
; 55(2): 187-94, 2007 Feb.
Article
in English
| MEDLINE | ID: mdl-17092602